Prosecution Insights
Last updated: August 18, 2026
Application No. 18/681,457

GENETICALLY ENGINEERED CELL-DERIVED VACCINES

Non-Final OA
Filed
Feb 05, 2024
Priority
Aug 13, 2021 — provisional 63/233,190 +1 more
Examiner
CHHAY, BONIRATH
Art Unit
1645
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Regents of the University of California
OA Round
1 (Non-Final)
75%
Grant Probability
Favorable
1-2
OA Rounds
5m
Est. Remaining
75%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allowance Rate
3 granted / 4 resolved
+15.0% vs TC avg
Minimal +0% lift
Without
With
+0.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
32 currently pending
Career history
29
Total Applications
across all art units

Statute-Specific Performance

§101
4.9%
-35.1% vs TC avg
§103
30.4%
-9.6% vs TC avg
§102
7.8%
-32.2% vs TC avg
§112
33.3%
-6.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 4 resolved cases

Prosecution Timeline

Feb 05, 2024
Application Filed
Jul 31, 2026
Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12685770
DEIMMUNIZED FLAGELLIN AND VACCINE COMPOSITION COMPRISING SAME
2y 7m to grant Granted Jul 21, 2026
Study what changed to get past this examiner. Based on 1 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
75%
Grant Probability
75%
With Interview (+0.0%)
2y 11m (~5m remaining)
Median Time to Grant
Low
PTA Risk
Based on 4 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month